We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Korchi, AM, Garibotto, V, Lovblad, K-O, Haller, S, Weber, DC. Radiologic patterns of necrosis after proton therapy of skull base tumors. Can J Neurol Sci. 2013;40(6):800–6.CrossRefGoogle ScholarPubMed
2
2.Levin, VA, Bidaut, L, Hou, P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79:1487–95.Google Scholar
3
3.Shah, AH, Snelling, B, Bregy, A, et al. Discriminating radiation necrosis from tumor progression in gliomas: a systemic review what is the best imaging modality?J Neurooncol. 2013;112:141–52.Google Scholar
4
4.Caroline, I, Rosenthal, MA. Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis?J Clin Neurosci. 2011;19:633–7.Google Scholar
5
5.Rahmathulla, G, Marko, NF, Weil, RJ. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. J Clin Neurosci. 2013;20:485–502.Google Scholar
6
6.Cha, J, Kim, ST, Kim, HJ, et al. Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression. Eur Radiol. 2013;23:879–86.Google Scholar
7
7.Rock, JP, Scarpace, L, Hearshen, D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery. 2004;54:1111–17.Google Scholar
8
8.Weybright, P, Sundgren, PC, Maly, P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol. 2005;185:1471–6.Google Scholar
9
9.Yamane, T, Sakamoto, S, Senda, M. Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging. 2010;37:685–90.CrossRefGoogle ScholarPubMed
10
10.Rachinger, W, Goetz, C, Pöpperl, G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505–11.Google Scholar
11
11.Pöpperl, GGötz, CRachinger, WGildehaus, FJTonn, JCTatsch, K. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464–70.Google Scholar
12
12.Chen, W, Cloughesy, T, Kamdar, N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945–52.Google Scholar
13
13.Enslow, MS, Zollinger, LV, Morton, KA, et al. Comparison of F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med. 2012;37:854–61.CrossRefGoogle Scholar
14
14.Gömez-Río, MRodríguez-Fernández, A, Ramos-Font, C, López-Ramírez, E, Llamas-Elvira, JM. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging. 2008;35:966–75.Google Scholar